Tech Company Financing Transactions

Apnimed Funding Round

Alpha Wave Ventures, Columbia Seligman Investments and Sectoral Asset Management invested in a $79.8 million Series C capital raise for Apnimed. This venture round was announced on 1/4/2023.

Transaction Overview

Company Name
Apnimed
Announced On
1/4/2023
Transaction Type
Venture Equity
Amount
$79,750,000
Round
Series C
Investors

Alpha Wave Ventures (Lead Investor)

Columbia Seligman Investments

Sectoral Asset Management (Stefan Larson)

Tao Capital Partners (Nicholas Pritzker)

Proceeds Purpose
The financing will fund the planned Phase 3 trials for Apnimed's lead candidate, AD109 (aroxybutynin + atomoxetine), that has the potential to be the first oral treatment for OSA. Enrollment for the clinical trials is expected to begin in the second quarter of 2023 subject to discussions with the U.S. Food and Drug Administration (FDA).

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
20 Holyoke St.
Cambridge, MA 02138
USA
Phone
(617) 500-8880
Website
www.apnimed.com
Email Address
Not Recorded
Overview
Apnimed was built upon a simple idea -- patients with Obstructive Sleep Apnea (OSA) need a safe and effective medication that addresses the underlying biology of the disease. OSA is a serious disorder in which the upper airway partly or completely closes during sleep.
Profile
Apnimed LinkedIn Company Profile
Social Media
Apnimed Company Twitter Account
Company News
Apnimed News
Facebook
Apnimed on Facebook
YouTube
Apnimed on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Larry Miller
  Larry Miller LinkedIn Profile  Larry Miller Twitter Account  Larry Miller News  Larry Miller on Facebook
Chief Financial Officer
Michael Rogers
  Michael Rogers LinkedIn Profile  Michael Rogers Twitter Account  Michael Rogers News  Michael Rogers on Facebook
Chief Medical Officer
Ron Farkas
  Ron Farkas LinkedIn Profile  Ron Farkas Twitter Account  Ron Farkas News  Ron Farkas on Facebook
Chief Operating Officer
Dennis Molnar
  Dennis Molnar LinkedIn Profile  Dennis Molnar Twitter Account  Dennis Molnar News  Dennis Molnar on Facebook
Chief Scientific Officer
Luigi Montemurro
  Luigi Montemurro LinkedIn Profile  Luigi Montemurro Twitter Account  Luigi Montemurro News  Luigi Montemurro on Facebook
VP - Bus. Development
Barry Wohl
  Barry Wohl LinkedIn Profile  Barry Wohl Twitter Account  Barry Wohl News  Barry Wohl on Facebook

 

 

Browse more venture capital transactions:

Prev: 1/4/2023: Alterpacks venture capital transaction
Next: 1/4/2023: Ganymed Robotics venture capital transaction

 

Share this article

 

Where The Data Comes From

We do our best to document every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.